Table 3 Percentage of leukocyte populations and cell ratios in patients with nAMD with and without subretinal fibrosis.

From: Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration

Variables

Controls (mean ± SD) n= 26

Fibrosis absent (mean ± SD) n= 66

Fibrosis present (mean ± SD) n= 37

Univariate analysis

Multivariate analysis (age and gender)

P value fibrosis absent vs present 1

P value fibrosis absent vs present 2

Odds ratio

95% confidence interval for odds ratio

Cell subsets (FSC/SSC plot)

 Lymphocytes (%)

30.45 ± 7.82

26.17 ± 7.4

27.11 ± 6.19

0.517

   

 Monocytes (%)

7.28 ± 1.88

8.09 ± 2.71

7.43 ± 2.32

0.215

   

 Neutrophils (%)

59.80 ± 8.73

63.80 ± 8.25

63.55 ± 6.37

0.869

   

 Neutrophil/Lymphocyte ratio

2.16 ± 0.84

2.75 ± 1.22

2.51 ± 0.77

0.515

   

Cell subsets (CD antigens)

 CD14+ (%)

7.35 ± 1.95

7.75 ± 2.39

7.35 ± 1.96

0.447

   

 CD4+ (%)

12.21 ± 3.92

10.82 ± 4.08

12.44 ± 4.37

0.042

0.026

37.08

1.53–899.43

 CD8+ (%)

5.86 ± 2.96

5.39 ± 3.8

4.51 ± 2.85

0.326

   

 CD19+ (%)

3.41 ± 2.16

2.95 ± 1.69

2.53 ± 1.07

0.249

   

 CD56+ (%)

3.27 ± 1.66

3.49 ± 1.57

3.42 ± 2.34

0.340

   

 CD11b+ (%)

67.40 ± 9.00

72.97 ± 8.47

72.48 ± 6.55

0.797

   

 CD16hiHLA-DR Neutrophils (%)

57.80 ± 9.05

63.33 ± 8.7

62.95 ± 6.21

0.798

   

 CD16hiHLA-DR/(CD4 + CD8) ratio

3.51 ± 1.49

4.60 ± 2.06

4.13 ± 1.56

0.462

   

 CD16hiHLA-DR/CD4 ratio

5.34 ± 2.34

6.80 ± 3.07

5.65 ± 1.97

0.120

   

 CD16hiHLA-DR/CD8 ratio

13.80 ± 11.28

19.10 ± 15.52

21.02 ± 17.48

0.381

   

 CD16hiHLA-DR/CD19 ratio

25.69 ± 21.26

31.16 ± 27.45

33.55 ± 26.44

0.354

   

 CD16hiHLA-DR/CD56 ratio

22.41 ± 11.25

22.91 ± 15.72

29.25 ± 23.86

0.274

   
  1. Bold P < 0.05; SD: Standard deviation.
  2. 1Independent samples t-test.
  3. 2Multivariable logistic regression; corrected for age and gender.